BMS loses to Teva

Therefore, we see no error in the selection of 2′-CDG
as the lead compound here. See Velander v. Garner, 348
F.3d 1359, 1377 (Fed. Cir. 2003) (“Obviousness, and
expectation of success, are evaluated from the perspective
of a person having ordinary skill in the art
at the time of invention
.” (emphasis added) (citation omitted));see also
Eisai , 533 F.3d at 1359



link: http://www.cafc.uscourts.gov/images/stories/opinions-orders/13-1306.Opinion.6-11-2014.1.PDF